AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026.
date: 2026-02-06 19:39:00
Related reading